

II. CLAIM AMENDMENTS

Claims 1-12 (Cancelled, without prejudice or disclaimer)

13. (New) A method of treatment or prevention of menopausal complaints, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation in the form of an immediate-release peroral dosage unit, comprising tibolone, wherein the pharmaceutical formulation has a bioavailability, *in vivo*, of 3rd-OH tibolone at a level above that provided by a solution of tibolone, wherein the amount of tibolone in the immediate-release peroral dosage unit and in the tibolone solution are substantially the same.
14. (New) The method of Claim 13, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 22.8 μm .
15. (New) The method of Claim 14, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 20 μm .
16. (New) The method of Claim 13, wherein the rate of dissolution of tibolone from the pharmaceutical formulation is such that when the pharmaceutical formulation is subjected to a dissolution-test, wherein a sample of said pharmaceutical formulation containing 2.5 mg of tibolone is exposed to a 0.25% sodium lauryl sulfate solution and the dissolution rate is measured, a $t_{50\%}$ value about 23.1 minutes is obtained.
17. (New) The method of Claim 16, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 22.8 μm .